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ceux de la littérature, un équipement devrait être acquis pour des biopsies
échoguidées.
http://dx.doi.org/10.1016/j.afju.2014.03.007
Biopsie prostatique transrectale au chu
yo: analyse de l’acceptabilite, de la
tolerance et des facteurs de risque de
complications
Service d’Urologie, Centre Hospitalier Universitaire Y.O, Burkina Faso
Objectif: étudier l’acceptabilité, la tolérance et les facteurs de risque de com-
plication des biopsies transrectales digito-guidées de la prostate au CHUYO
de Ouagadougou
Patients et Méthodes: Il s’est agi d’une étude transversale à caractère analy-
tique. Cette étude s’est déroulée du 01er Mai au 31 Novembre 2012. Tous les
patients ayant subi une biopsie prostatique pendant la durée d’étude ont été
inclus. Les paramètres liés aux caractéristiques sociodémographiques des
patients ont été recueillis, un questionnaire semi structuré recueillant des
informations sur l’acceptabilité, la tolérance du geste ainsi que la recherche
des facteurs de risque de complications a été administré à chaque patient.
Les données étudiées ont été évaluées en termes de fréquence, de moyenne
et d’écart-type.
Résultats: Soixante-sept patients avec un âge moyen de 71,7 ans ont été
admis dans l’étude.
Soixante-sept virgule un pour cent des patients n’ont pas éprouvé de gêne au
cours de la biopsie. 63 patients soit 94% se disaient être prêts pour une reprise
du geste. 64,2% connaissaient le nom de l’acte. 26,9% avaient rec¸u au préal-
able l’information sur la technique de la biopsie et 14,9% l’information sur
les risques encourus, les éléments de surveillance et les modalités de prise en
charge en cas de complications. La pathologie hémorroïdaire était présente
dans 16,4% des cas et des facteurs immunodépresseurs dans 4,5% des cas..
3% des patients étaient non-compliants dans l’antibioprophylaxie. La rela-
tion entre la qualité relationnelle médecin-malade et le niveau de la tolérance
n’était pas statistiquement significative. Il n’y avait pas de corrélation entre
les facteurs de risque infectieux et la survenue de ces complications. Le
lavement évacuateur ne jouait pas sur la survenue de ces complications non
plus.
Conclusion: la biopsie transrectale était bien tolérée dans notre pratique
courante. Cette étude a fourni une occasion d’amorcer une véritable com-
munication entre médecin et malade.
http://dx.doi.org/10.1016/j.afju.2014.03.008
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hyperplasia
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4236, Accra, Ghana
Introduction: An increased blood transfusion rate in open prostatectomy for
benign prostate hypertrophy (BPH) is well noted. In developing countries
where open prostatectomy is currently mostly practiced, assess to blood
for blood transfusion is limited as there is less voluntary blood donation.
These surgeries are sometimes unduly delayed on account of lack of accept-
able replacement donors. Blood transfusion also carriers risk of transfusion
reactions and disease dissemination as well as a substantial economic cost.
Being able to determine the factors that predispose a patient to receiving
blood transfusion peri-operatively at open prostatectomy will enable a more
rational blood product management for the procedure.
Objectives: To determine the factors predisposing to peri-operative blood
transfusion in open prostatectomy for BPH that will subsequently form a
basis towards blood product management for the procedure.
Methods: This was a prospective study of consecutive patients who under-
went open prostatectomy for benign prostate hyperplasia from January 2010
to June 2012 at the Urology Unit of the Korle Bu Teaching Hospital Accra,
Ghana.
The patients scheduled for open prostatectomy for BPH underwent anaes-
thetic evaluation with the determination of the hemoglobin level and the
presence of co-morbidities. The patients who were found fit and consented
to undergo either transvesical open prostatectomy or retropubic open pros-
tatectomy and the study were considered. The additional data collected and
imputed into the proforma included the case type – elective or emergency,
the indication for the surgery, the anaesthetic method used, the status of the
operating surgeon – consultant or resident, the duration of surgery, prostate
weight, and the estimated blood loss.
Also documented was the units of blood transfused peri-operatively. The
data was analyzed using the statistical package for the social sciences (SPSS)
version 16.
Results: One hundred and forty-nine patients were studied. The mean age of
the patients was 69.9 ± 9.0 years (range 48–92yrs). One hundred and thirty
(87.2%) of the cases were elective cases while 19 (12.8%) were emergen-
cies. With regards to the indication for the prostatectomy, 66.4% was as a
result of refractory retention of urine, 22.1% haematuria due to BPH, 6.7%
severe lower urinary tract symptoms, 3.4% BPH with associated bladder
calculi, 0.7% BPH with obstructive uropathy and 0.7% refractory reten-
tion with stuck urethral catheter. The mean pre-operative haemoglobin level
was 12.0 ± 2.4 g/dl (range 3.1–16.4 g/dl). With regards to the presence of
co-morbidities, 83 (55.7%) of the patients had no co-morbidities while 66
(44.3%) had associated co-morbidities such as hypertension and diabetes
mellitus.
Seventy (47.0%) of the surgeries were performed by residents while 79
(53.0%) of the surgeries were by consultants. Open transvesical prosta-
tectomy was the operative method used in 133 (89.3%) with retropubic
prostatectomy in 16 (10.7%). The mean operative time was 102.3 ± 31.6 min
(range 35.0–230.0 min) with 123 (82.6%) of the surgeries done under spinal
anesthesia, 20 (13.4%) under general anaesthesia and 6 (4.0%) with epidu-
ral anaesthesia. The mean operative prostate weight was 112.5 ± 91.1 g
(range 15–550 g) and the estimated blood loss ranged from 100 to
2400 ml.
The peri-operative blood transfusion rate was 21.5% (32/149), a total of
68 units of blood were transfused. The transfusion rate as seen at various
haemoglobin levels were, 84.6% in patients with Hb level ≤ 8.0 g/dl, 75%
(Hb 8.1–9.0), 60% (Hb 9.1–10.0), 25% (Hb 10.1–11.0), 10% (Hb 11.1–12.0),
15.4% (12.1–13.0), 2.8% (Hb 13.1–14.0) and no transfusion in patients with
Hb > 14.0 g/dl.
There was a significantly higher blood transfusion rate in emergencies cases
compared to elective cases (X2 = 42.651, p < 0.001) and in patients with-
out co-morbidities compared to patients with co-morbiditeis (X2 = 4.596,
p < 0.05). Compared to spinal anaesthesia, patients that underwent the
procedure under general anaesthesia had a higher blood transfusion rate
(X2 = 7.585, p < .05).
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In a logistic regression analysis, the only significant associations with blood
transfusion in open prostatectomy were the duration of surgery (.042), co-
morbidity (.006) and the pre-operative haemoglobin level (.000).
Conclusion: The intra-operative blood transfusion rate in open prostatec-
tomy for BPH in this series was 21.5%. Blood transfusion rate was associated
with and significantly higher in emergency surgeries, in the absence of
co-morbidities and with procedures done under general anaesthesia. Using
logistic regression analysis, the main determinants of transfusion were the
duration of surgery, comorbidity and the pre-operative haemoglobin level.
http://dx.doi.org/10.1016/j.afju.2014.03.009
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Introduction: Testicular atrophy in patients with prostate cancer (CaP) has
been associated with poor outcome. We have previously reported that 65%
of our newly diagnosed CaP patients treated with bilateral orchidectomy
had testicular atrophy. This is a pilot retrospective study evaluating the rela-
tionship between histologic grade and severity of testicular atrophy in these
patients.
Methods: Data was collated from records of patients who had therapeu-
tic bilateral orchidectomy for prostate cancer between 2002 and 2012. The
Histology was reported by a Consultant Pathologist. Testicular atrophy was
graded as none (normal), mild, moderate or severe based on the degree of
testicular tubular sclerosis found at histology. CaP specimens were graded
using the Gleason scoring systems. Analysis was done using SPSS version
18.
Results: The histology of 164 prostate biopsies and 113 orchidectomy speci-
mens from prostate cancer patients were analyzed. The age range was 36-91
years; mean age was 69.23 years (SD 9.446 years). The Gleason’s score
ranged 4–10, mean 6.95 (SD 1.44). 64 patients (39%) had GS of 4–6, 87
(53%) had GS of 7–8 and 13 (8%) had GS 9–10. 21 (18.6%) had normal
testis, 39 (34.5%) had mild, 16 (14.2%) had moderate and 37 (32.7%) had
severe testicular atrophy. There was no statistically significant difference in
GS among the four groups; F = 1.555; Sig. 0.221.
Conclusion: Most patients in our environment with advanced prostate cancer
have testicular atrophy, the degree of which is unrelated to histology grade
of the tumour.
http://dx.doi.org/10.1016/j.afju.2014.03.010
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Objectives: To study clinical incidence of histologically proven PC, TNM
stage and management outcomes
Methods: Case expansion study of PC managed in Accra, abstracted records
2004–2012.
Diagnosis by history, Hogh PSA, physical and abnormal DRE and his-
tologically confirmed by biopsy. With gleason scores (GS) and TNM
staged and managed by approved protocols. Organ confined PC by radical
prostatectomy (RP), brachytherapy (BRCHY), external beam radiotherapy
(EBRT), Hormonal/Chemotherapy, or surveillance if life expectancy less
than 15 years. T3-4M0 treated by hormonal/chemotherapy ± Total androgen
blockade (TAB), BRCHY/EBRT. Metastatic T1-4-M1 is treated by hor-
monal/chemotherapy ± TAB. Significant LUTO is treated by alpha blockers,
TUIP/TURP.
Results: There were 669 cases median age 70 years, median GS 7,organ
confined PC 415 (62%), T3-4 M0 167 (25%), METASTATIC CASES 87
(13%). The report on 669 cases were followed for 1–7 years is as follows.
A. Organ Confined T1-2 N0 M0 PC – n = 415 presentation is asymptomatic.
Symptomatic cases 1–20% treatment regimes
i) Radical Prostatectomy – n = 92. Open retropubic/prior median PSA
16.1 ng/ml, post PSA 0.23 ng/ml. RP specimen BPH = 3, organ con-
fined 76, positive margins 13. Complications rate (COMP) 3–22%.
ii) Brachytherapy – n = 70.145 GY, median prior PSA 14.6 ng/ml, post
PSA 0.59 ng/ml. COMP 3–10%.
iii) EBRT no = 155. 70/74GY. Median prior PSA 15.7 ng/ml post PSA
0.54 ng/ml. COMP 2–6%.
iv) Hormonal Chemotherapy + TAB – n = 98 prior median PSA
48.5 ng/ml, post PSA 0.6 ng/ml. METHODS LHRH analogue
/Chemotherapy 41%, stilboesterol 29%, BTO 30%. COMP 4–30%.
v) Surveillance GS 6.prior PSA < 8 ng/ml. Presentation symptomatic
60%.
All had neoadjuvant hormonal/chemotherapy + TAB, LHRH 52%,
stilboesterol 12%, BTO36% then
i) Bachytherapy – T3N3, prior PSA 14.6 ng/ml, post PSA 0.11 ng/ml.
ii) EBRT. no-64. Prior PSA T3 (34%) 32.4 ng/ml, T4 (2%) 64.6 ng/ml,
Post PSA T3 0.6 ng/ml, T4 0.4 ng/ml, COMP = 2–70%.
iii) Hormonal chemotherapyn = 103 (T3 24%, T4 38%), LHRH 28%
stilboesterol 4%, BTO 30%, COMP 4–35%, Hospitalmortality
26.3%.
